Core Insights - Yidu Technology reported total revenue of 715 million RMB for the fiscal year ending March 31, 2025, with adjusted EBITDA showing a 25.6% year-on-year increase, indicating sustained profitability after a previous loss [1] - The company reduced its annual loss to 135 million RMB, a 38.9% decrease compared to the previous year, supported by improved operational efficiency and enhanced synergy across business segments [1] - The order backlog reached 789 million RMB, reflecting strong demand for the company's services [1] Business Performance - The AI for Medical segment generated revenue of 346 million RMB, a 10.3% increase year-on-year, with a total of 110 clients from well-known hospitals and 44 clients from regulatory bodies [3] - The AI for Life Science segment achieved revenue of 247 million RMB, with 132 active clients and an 87.51% revenue retention rate among the top 20 clients, including 16 of the top 20 multinational pharmaceutical companies [4] - The AI for Care segment reported revenue of 122 million RMB, with significant participation in health insurance projects, covering over 6.09 million people in Shenzhen and more than 15 million in Beijing [5] Technological Advancements - The YiduCore algorithm engine processed over 6 billion authorized medical records, covering more than 4,000 hospitals and providing insights into thousands of diseases [1] - The company developed an AI platform that integrates multiple large models to enhance various medical scenarios, achieving deployment in over 30 top-tier hospitals within three months [2] - The iEDC solution for clinical data management significantly improved data governance processes, while the iRecruitment tool enhanced patient recruitment accuracy by over three times [5] Future Outlook - Yidu Technology plans to deepen the application of AI in healthcare, focusing on product iteration and operational efficiency to drive the intelligent upgrade of the medical industry [6]

Core Insights - The company reported a revenue of RMB 715 million for the fiscal year ending March 31, 2025, representing a year-on-year decrease of 11.4% [1] - The loss attributable to shareholders was RMB 118 million, a reduction of 39.58% compared to the previous year, with a loss per share of RMB 0.11 [1] Business Performance - The company has developed the "AI Medical Brain" YiduCore, which has established a comprehensive barrier across data, computing power, algorithms, and scenarios, processing 1.15 billion patient visits and 6 billion authorized medical records [1] - The company has achieved a leading position in technology validation, evidenced by top performance in evaluations organized by the National Health Commission [1] - The company has deployed its AI platform in over 30 top-tier hospitals, demonstrating its capability to transition from technology validation to industrial value [1][2] Client Engagement and Solutions - The company has provided solutions to 110 top hospitals and 44 regulatory bodies, covering over 4,000 hospitals, and has upgraded its AI and data platforms to versions 2.0 and 5.0 respectively [3] - The company serves 132 life sciences clients, with a revenue retention rate of 87.51% among its top 20 clients, including 16 of the top 20 multinational pharmaceutical companies [3] - The company has maintained its position as the main operating platform for "Shenzhen Huimin Insurance" and "Beijing Huimin Insurance," with insured individuals reaching 6.09 million and over 15 million respectively [3] Financial Health - The company’s total revenue for the fiscal year was RMB 715 million, down 11.4% due to external market conditions and product mix changes, but the annual loss was reduced to RMB 1.35 billion, a decrease of 38.9% [4] - The company has improved cash management, resulting in a 23.8% reduction in cash outflow from operating activities year-on-year, with cash reserves totaling RMB 3.309 billion [4]

Financial Performance - For the fiscal year ending March 31, 2025, the total revenue of Yidu Tech Inc. was RMB 714.979 million, a decrease of 11.4% compared to RMB 807.076 million in the previous fiscal year[6]. - The gross profit for the same period was RMB 239.182 million, reflecting a decline of 29.5% from RMB 339.445 million in the previous year[6]. - The annual loss decreased to RMB 135.223 million, down 38.9% from RMB 221.242 million in the previous year[6]. - Revenue decreased by 11.4% from RMB 807.1 million for the fiscal year ending March 31, 2024, to RMB 715.0 million for the fiscal year ending March 31, 2025[37]. - Revenue from the life sciences solutions segment decreased by 23.7% from RMB 324.0 million to RMB 247.1 million during the same period[37]. - Revenue from the health management platform decreased by 28.0% from RMB 169.5 million to RMB 122.0 million[37]. - Gross profit for the fiscal year ending March 31, 2025, was RMB 239.2 million, with a gross margin of 33.5%[39]. - The company reported a net loss of RMB 135,223,000 for the fiscal year, compared to a net loss of RMB 221,242,000 in the previous year[85]. - The financial income for the fiscal year was RMB 2,321,000, a decrease from RMB 10,510,000 in the previous year[85]. - The company experienced a foreign exchange loss of RMB 50,420,000 during the fiscal year, compared to a loss of RMB 122,837,000 in the previous year[87]. Operational Highlights - The company served 110 top hospitals and 44 regulatory bodies, covering over 4,000 hospitals with its big data platform and solutions[11]. - The number of active users on the health management platform exceeded 24 million, with 6.09 million participants in the "Shenzhen Hui Min Bao" insurance program for 2024[11]. - The retention rate for the top 20 life science clients was 87.51%, with 16 out of the top 20 multinational pharmaceutical companies being clients[11]. - The company has developed the YiduCore AI medical brain, which has processed 11.5 billion patient visits and 60 billion authorized medical records[9]. - The AI diagnosis assistant served a total of 26,000 patients from February to June 2025, providing personalized decision-making support during medical consultations[15]. - The company ranked first in a national large model capability assessment organized by the National Health Commission in September 2024[14]. Technology and Innovation - The AI platform has been deployed in over 30 top-tier hospitals within three months of launch, significantly enhancing operational efficiency and reducing application deployment time by approximately 50%[15]. - The new generation data center Eywa 5.0 has improved data flow speed and efficiency by over four times, significantly reducing labor and computing costs[17]. - The AI platform can reduce the time for medical record writing from 5 minutes to 30 seconds, and TNM staging assessment time by 70%[17]. - The company plans to enhance AI technology and optimize the YiduCore algorithm for better performance in complex tasks[32]. - The company aims to deepen disease research and application, providing AI decision support for core diseases like tumors and cardiovascular diseases[32]. Cost Management - Sales and marketing expenses decreased by 33.4% from RMB 208.9 million for the fiscal year ending March 31, 2024, to RMB 139.2 million for the fiscal year ending March 31, 2025, representing 19.5% of revenue, down from 25.9%[42]. - Administrative expenses decreased by 14.6% from RMB 171.3 million for the fiscal year ending March 31, 2024, to RMB 146.4 million for the fiscal year ending March 31, 2025, accounting for 20.5% of revenue, down from 21.2%[43]. - R&D expenses decreased by 19.9% from RMB 232.9 million for the fiscal year ending March 31, 2024, to RMB 186.5 million for the fiscal year ending March 31, 2025, representing 26.1% of revenue, down from 28.9%[44]. - Total expenses for sales and service costs, sales and marketing expenses, administrative expenses, and R&D expenses totaled RMB 947,824 thousand in 2025, down from RMB 1,080,767 thousand in 2024, a decline of 12.3%[106]. Future Outlook - Future plans include continuous product upgrades to enhance coverage in general hospitals and empower specialized hospitals through a three-in-one collaborative system[19]. - The company will explore new models for AI-enabled health management services to increase active user numbers[35]. - The company is focused on strategic partnerships, investments, and acquisitions to enrich its ecosystem[32]. Employee and Financial Position - The total number of employees as of March 31, 2025, was 823, with 326 in product R&D and technology, 277 in the medical department, 142 in sales and marketing, and 78 in general and administration[61]. - Total compensation costs for the fiscal year ending March 31, 2025, amounted to RMB 417.6 million, down from RMB 566.3 million for the fiscal year ending March 31, 2024[62]. - Cash and cash equivalents, along with other deposits, totaled RMB 3,309.1 million as of March 31, 2025, down from RMB 3,409.9 million as of March 31, 2024[49]. - The company had no significant acquisitions or disposals of subsidiaries or associated entities for the fiscal year ending March 31, 2025[51]. - The company did not declare or pay any dividends for the years ended March 31, 2025, and 2024[116].

Core Insights - The 2025 Summer Davos Forum will be held in Tianjin from June 24-26, focusing on the theme of "Entrepreneurial Spirit in the New Era" [1] Group 1: AI in Healthcare - AI technology can significantly enhance the quality of medical diagnosis and treatment by integrating years of patient medical history into a visual timeline, allowing doctors to better understand patient conditions [3] - The AI decision support system can provide multiple treatment suggestions for complex cases, aiding doctors in making more accurate clinical decisions [3] - Clinical trial costs have been reduced by 30%-40% due to the integration of AI and data platforms, which can automate many previously manual processes [3] Group 2: Industry Challenges and Opportunities - The healthcare industry is challenging to navigate, with recent market and policy changes prompting the company to adopt a cautious approach to commercialization [4] - The recent activity in the secondary market for innovative drugs reflects a valuation correction, recognizing China's potential as a research-driven market [4] - The Chinese biopharmaceutical ecosystem is expected to grow, with more companies pursuing international collaborations and contributing to global healthcare [4] Group 3: Future Outlook - Future healthcare scenarios envision the integration of historical medical data with wearable devices, providing a comprehensive understanding of individual health and 24/7 personalized health advice through AI [5] - AI is expected to significantly lower new drug development costs, helping more drugs avoid the "orphan drug" dilemma [5] - Insurance coverage is anticipated to expand, with initiatives like the company's "Hui Min Bao" providing coverage for a wide range of patients, including those with pre-existing conditions [5]

Group 1 - The core viewpoint is that Yidu Technology is becoming a key target for public funds due to its "AI + healthcare" dual-driven strategy, with significant stock price increases reflecting market recognition of its AI healthcare layout [1][2] - Public funds have been intensively increasing their positions in Yidu Technology, with notable allocations such as 8.84% by Ping An Medical Selected Fund and a complete shift by Yinhua Medical Health Fund towards AI healthcare stocks [2][3] - The commercialization of AI in healthcare is accelerating, with Yidu Technology's technology demonstrating significant value in chronic disease management, drug development, and clinical decision support, supported by government policies [3][5] Group 2 - As the AI healthcare trend rises, public funds are beginning to explore underrepresented stocks, with Yidu Technology leading in stock price increases since April, indicating growing institutional interest [4] - Institutions are optimistic about the long-term potential of Yidu Technology, which aligns with the trend of integrating AI into the pharmaceutical industry, positioning it as a benchmark in the Hong Kong AI healthcare sector [5]

Summary of the Conference Call for Yidu Technology Industry Overview - National policies and local government support are accelerating the commercialization of AI in healthcare, particularly in ICU settings, where AI-assisted diagnosis has been included in medical service pricing projects, promoting the development of medical AI [2][4] - There is a significant difference in the application of AI in drug development versus diagnostic services, with diagnostic services advancing more rapidly and already being applied in pre-diagnosis, diagnosis, and post-diagnosis stages, enhancing efficiency and accuracy [2][5] Company Insights - Yidu Technology's main business includes big data platforms and solutions (for hospitals and regulatory agencies), life sciences solutions (for pharmaceutical companies), and health management platforms (for public health insurance), having served numerous top hospitals and pharmaceutical clients [2][10] - The company has connected its DeepSeek technology to 420 hospitals, with over 50% being top-tier hospitals [6] - Yidu Technology has launched a hardware-software integrated AI platform, compatible with mainstream chips and open-source large models, which has been implemented in over 20 hospitals and is expected to boost revenue [3][16] Financial Performance and Projections - The company operates on a fiscal year ending March 31, with expectations to break even in fiscal year 2026 or 2027, driven primarily by the big data platform [3][17] - The gross margin remains stable at around 40%, with good expense control, but the company has not yet achieved profitability [17] - The big data platform and solutions are expected to be the main growth drivers, while life sciences solutions are projected to recover in fiscal years 2026 to 2027 [18] Key Business Metrics - The big data platform has covered 2,800 hospitals and accumulated over 800 specialized disease databases, serving more than 40 health commission agencies [11] - The life sciences solutions segment serves 71 pharmaceutical companies, with a retention rate exceeding 100% for top clients [12] - The health management platform has reached 24 million users, providing a solid customer base for future C-end business development [14] AI Technology Impact - The company has processed and analyzed data from over 1.1 billion patient visits and 5.5 billion authorized medical records, ranking first in specific scenarios such as medical knowledge Q&A and medical language understanding [15] - The integration of DeepSeek into its framework and partnerships with major companies like Huawei and ByteDance help maintain industry leadership and expand the product ecosystem [15] Valuation and Target Price - The initial coverage uses a price-to-sales (PS) valuation method, with a target price of HKD 77 per share, based on a PS ratio of 77.7, and a buy rating assigned [19]

Summary of Conference Call Notes Company Overview - The company discussed is Yidu Technology, a pioneering innovator in the AI healthcare industry with a focus on deepening its expertise over the past decade [1][2]. Key Points and Arguments Industry and Data - Yidu Technology has accumulated 5.5 billion high-quality medical records, covering over 1.1 billion patient visits, which is a significant asset in the Chinese healthcare landscape where data is not typically available post-discharge [1][20]. - The company has developed a comprehensive disease knowledge graph that encompasses all known diseases, supported by various specialized datasets and models [2][19]. Product and Application - The company offers a range of products, including a project management platform and an AI middle platform, which have seen accelerated project orders and implementations since the Chinese New Year, with over 20 projects currently in progress [3][4]. - The AI middle platform integrates multiple open-source models and has already been implemented in several hospitals, demonstrating its practical application in real-world settings [3][10]. Market Position and Competition - Yidu Technology is positioned as a key player in the AI healthcare market, with a belief that the market is still in its early stages and not yet saturated with competition [8][24]. - The company emphasizes that its competitive edge lies in its extensive data accumulation, algorithmic depth, and application scenarios, which are superior to many competitors in the field [20][33]. Financial Performance and Growth - The company anticipates a 10% annual growth in paid services, with a current coverage of 2,800 hospitals, including 105 top-tier hospitals and over 40 regulatory government clients [4][29]. - There is an expectation of improved financial performance and profitability sooner than previously guided, with a focus on enhancing the gross margin through product mix adjustments [29][30]. Collaboration and Partnerships - Yidu Technology has established a deep partnership with Huawei, leveraging their chip technology and exploring further collaboration opportunities in the healthcare sector [6][7]. - The company is also exploring partnerships with various hospitals and government projects, indicating a robust pipeline of collaborative opportunities [9][16]. Challenges and Future Outlook - The company acknowledges challenges in expanding into lower-tier hospitals due to budget constraints but sees potential for future growth as technology costs decrease and demand for intelligent healthcare solutions increases [41][43]. - There is a strong belief that the AI healthcare market will continue to grow, driven by policy support and increasing hospital budgets for technology investments [16][17]. Miscellaneous Insights - The company has noted a significant increase in project budgets from hospitals and government clients, with some budgets rising from millions to tens of millions [16][17]. - Yidu Technology's AI capabilities are designed to assist in various clinical scenarios, including complex cases, showcasing the versatility and depth of its technology [12][36]. Conclusion Yidu Technology is positioned as a leader in the AI healthcare sector, with a strong foundation of data, innovative products, and strategic partnerships. The company is optimistic about future growth, driven by increasing demand for intelligent healthcare solutions and supportive policies.

医渡科技 20250320 摘要 • 医渡科技构建了核心算法引擎——医渡引擎，通过深度挖掘数据价值，截 至 2024 年 9 月 30 日，已处理分析 51 亿份医疗记录，覆盖 10 亿人次，数 据量远超行业平均水平，并深度介入全国前 150 家顶级研究型医院中的 105 家，确保数据质量和算法精准度。 • 公司业务涵盖大数据平台与解决方案（面向医院和政府，项目制，百万至 千万级）、生命科学解决方案（覆盖全球前二十大国际药企中的 16 家，聚 焦核心用户，收入留存比例超 117%）以及健康管理平台与解决方案（覆盖 四省十二市，如北京和深圳），实现全场景覆盖。 • 2025 年春节后，医院对 AI 需求激增，医渡科技的模型调用开源模型并在 东南大学开发专业肝病 AI 医生，获钟南山院士认可。与中山肿瘤医院联合 开发 120 个新应用场景，AI 中台提供五层代码工具链，医生可定制专属 AI agent，30 秒内生成专用场景 AI 助手。 • 医疗数字化效能显著提升，训练资源利用率提高 25%，关键任务准确率提 高 5%-20%，上线周期缩短 50%。千万级别订单增多，但多数医院预算未达 标，公司根据预算调整产品 ...

医渡科技在 AI 医疗行业的业务进展和未来规划是什么？ 医渡科技在 AI 医疗行业深耕近十年，已接入 105 家顶级研究型医院，累计 55 亿份真实医疗数据。这些高质量数据在患者流动和疾病知识图谱方面展现了巨 大价值。公司业务分为三大板块：面向医院和政府的大数据平台与解决方案、 面向药企的生命科学解决方案，以及健康管理平台与解决方案。第一板块主要 通过项目制为医院和监管机构提供智能化平台，如去年推出的 AI 中台及全面数 据库等产品，ASP 从百万级提升至千万级。第二板块围绕药品和器械全生命周 期提供智能化解决方案，涵盖临床开发设计到上市后营销。第三板块则包括慢 病管理、商业险、惠民保险等健康管理服务，目前惠民保业务覆盖四省十二市， • 医渡科技业务涵盖大数据平台与解决方案（面向医院和政府）、生命科学 解决方案（面向药企）以及健康管理平台与解决方案。AI 中台等产品 ASP 提升至千万级，惠民保业务覆盖四省十二市，活跃用户超 2,400 万。 • 医渡科技与华为合作推出深圳一体机，但因医院需求差异大，销售未达预 期。公司采用多种底层技术框架，适配不同芯片，以满足各类医疗场景需 求，并持续优化算法引擎。 • 公 ...

医渡科技 摘要 Q&A 一度科技在 AI 医疗赛道中相比同行的最大优势是什么？公司成立的初衷和目标 是什么？ 在当前的医疗环境中，数据质量是推动大模型功能进化的关键因素。高质量医 疗数据获取难度较大，美国疾病数据可以交易，而中国所有数据都不出院，这 限制了模型性能提升。许多通用类大模型虽然尝试应用于 AI 医疗，但由于缺乏 临床真实数据，对疾病理解有限。一度科技过去十年深耕该赛道，从最早基于 Transformer 架构的小模型发展到现在的大模型，累计了 55 亿份真实医疗数据。 公司未来在研发投入和垂直产品发布节奏方面如何把控？ 目前一度科技的大模型已经能够完全赋能各个业务，但我们仍将持续投入，以 拓展更多应用场景并保持技术领先地位。预计每年研发投入约 8,000 万至 1 亿 元，其中一半用于算力方面，另一半用于人工成本。这种持续高研发和高投入 是必然的，以确保公司在 AI 医疗领域保持竞争优势并推动行业变革。 相较于传统的医疗信息化，医疗 AI 是否可以更直接地为病患带来益处？具体有 哪些方面能够让病患和医生受益？ 过去十年是医疗信息化建设的过程，而未来十年将是向医疗智能化发展的过程。 大模型作为多任务 ...